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Abstract 
Background: Thuricin CD is a two-component antimicrobial, belonging to the recently designated sactibiotic 
subclass of bacteriocins. The aim of this study was to investigate the effects of thuricin CD, as well as the antibiotics, 
tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide when used independently and when combined at 
low concentrations on the viability of Clostridium difficile 20291 R027, TL178 R002, Liv022 R106, DPC6350 and VPI10463 
biofilms and planktonic cells.
Results: On the basis of XTT (2,3-bis[2-methyloxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide)-menadi-
one biofilm viability assays, we found that thuricin CD was effective against biofilms of R027, Liv022 R106 and DPC6350 
when used independently while nitazoxanide and rifampicin were also potent against biofilms of R027 and DPC6350, 
when applied on their own. Tigecycline was found to be effective against R027 and DPC6350 biofilms, whereas teico-
planin and vancomycin when used independently were only effective against DPC6350 biofilms. The efficacies of the 
antibiotics rifampicin, tigecycline, vancomycin and teicoplanin against C. difficile 20291 R027 biofilms were significantly 
potentiated when combined with thuricin CD, indicating effective antimicrobial combinations with this sactibiotic 
against R027 biofilms. However, the potency of nitazoxanide against R027 biofilms was significantly diminished when 
combined with thuricin CD, indicating an ineffective combination with this sactibiotic against R027 biofilms. Paired 
combinations of thuricin CD along with these five antibiotics were effective at diminishing the viability of DPC6350 bio-
films. However, such combinations were largely ineffective against biofilms of TL178 R002, Liv022 R106 and VPI10463.
Conclusions: To the best of our knowledge, this is the first study to highlight the activity of a sactibiotic bacteriocin 
against biofilms and the first to reveal the potency of the antibiotics tigecycline, teicoplanin and nitazoxanide against 
C. difficile biofilms. On the basis of this study, it is apparent that different strains of C. difficile possess varying abilities 
to form biofilms and that the sensitivities of these biofilms to different antimicrobials and antimicrobial combinations 
are strain-dependent. Since the formation of relatively strong biofilms by certain C. difficile strains may contribute to 
increased cases of antibiotic resistance and recurrence and relapse of C. difficile infection, the findings presented in 
this study could provide alternative strategies to target this pathogen.
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Background
Clostridium difficile infection (CDI) is a major healthcare 
concern, especially in the European Union and North 
America [1]. In recent years, the formation of biofilms 
by C. difficile, which could contribute to antibiotic resist-
ance and CDI treatment failures has been highlighted 
[2, 3]. Indeed, increased resistance of C. difficile to van-
comycin and metronidazole and recurrence of disease 
due to treatment failure have already been reported [4]. 
Thus, there is a growing need to find alternative solutions 
to combat this pathogen. Two of the most problematic 
C. difficile biofilm producers are strains 20291 R027 and 
strain 630 [5]. Recent studies have provided insights into 
the mechanisms by which C. difficile forms biofilms [2, 3, 
5]. Dawson et al. demonstrated that the ability of C. diffi-
cile to produce biofilms involves the formation of several 
layers of bacteria in a complex matrix which is composed 
of polysaccharides, proteins and DNA [2]. Furthermore, 
Dapa et  al. showed that a quorum sensing regulator, 
LuxS, flagellae and Cwp84 are all needed for optimal C. 
difficile biofilm formation [5]. The authors of the study 
also found that there could be a potential link between 
the ability to form biofilms and sporulation, as C. diffi-
cile strains with a mutation in the gene encoding SpoOA, 
which is a transcription factor needed for sporulation, 
lacked the ability to form biofilms [5].
In this study, we provide insights into the potencies of 
various antimicrobials and antimicrobial combinations, 
when combined at relatively low concentrations against 
various C. difficile biofilms and compare and contrast the 
effects of these combinations against planktonic cells of 
the same strains. We note that thuricin CD is effective 
at targeting the biofilms of R027, R106 and DPC6350 at 
relatively low concentrations, while paired combinations 
of this bacteriocin with the antibiotics teicoplanin, tige-
cycline, vancomycin or rifampicin are potent at attenuat-
ing the viability of adherent biofilms formed by C. difficile 
strains 20291 R027 and DPC6350.
Methods
Thuricin CD purification
Thuricin CD was purified as described by Rea et  al. 
with minor modifications [6]. Briefly, brain heart infu-
sion (BHI) broth was first clarified using XAD-16 beads 
(Sigma Aldrich) prior to autoclaving. The thuricin CD-
producing strain Bacillus thuringiensis DPC6431 was 
subcultured two times in BHI broth prior to inoculating 
1.5 L of clarified BHI broth and grown overnight at 37º C 
with vigorous agitation. The overnight culture was cen-
trifuged at 8260g for 20  min and both the supernatant 
and cell pellet were kept for further use. The cell pellet 
was resuspended in 300  ml of 70  % isopropanol (IPA), 
0.1  % TFA and stirred for 4  h at 4  ºC. The supernatant 
was passed through fresh XAD-16 beads in a column and 
subsequently washed with 500 ml of 35 % ethanol. Thu-
ricin CD was eluted in 400  ml of 70  % IPA, 0.1  % TFA 
and this elute was called S1. The cell pellet which was 
resuspended in 70 % IPA, 0.1 % TFA was centrifuged at 
8260g for 20 min and the supernatant (S2) was combined 
with S1. All the IPA was removed by using rotary evap-
oration (Buchi) and the sample passed through a Phe-
nomenex C-18 column which had been pre-equilibrated 
with methanol and water. The column was washed with 
120 ml of 35 % ethanol and thuricin CD eluted in 75 ml 
of 70 % IPA, 0.1 % TFA. This was further concentrated by 
removing the IPA using rotary evaporation, prior to sepa-
rating the two peptides using reverse-phase high perfor-
mance liquid chromatography (RP-HPLC).
Minimum inhibitory concentrations (MICs) determinations
The antibiotics rifampicin, teicoplanin, tigecycline, van-
comycin and nitazoxanide for this study were purchased 
from Sigma Aldrich. The MICs of the sactibiotic, thuricin 
CD and the antibiotic vancomycin against C. difficile 
strains 20291 R027, TL178 R002 and Liv022 R106  had 
already been determined in our previous study [7]. MICs 
of the antibiotics teicoplanin, tigecycline, rifampicin 
and nitazoxanide against planktonic cells of C. difficile 
strains 20291 R027, Liv022 R106, TL178 R002, DPC6350 
and VPI10463 were determined in this study and all 
assays were conducted as described in Mathur et al. [7]. 
Briefly, reinforced clostridium medium (RCM), previ-
ously boiled and cooled under anaerobic conditions, 
was used for overnight cultures of the various C. diffi-
cile strains, grown at 37 °C in an anaerobic chamber for 
16 h. The antibiotics were weighed out and resuspended 
initially in RCM broth (for teicoplanin, tigecycline, van-
comycin and rifampicin) and DMSO for nitazoxanide. 
Antibiotics were subsequently diluted in RCM broth 
to give the desired starting concentrations and serially 
diluted in 96-well microtitre plates. Overnight cultures 
of C. difficile strains were subcultured until they reached 
mid-logarithmic phase (OD600 of approximately 0.5), at 
which point they were inoculated into the wells of the 
microtitre plates, with a final inoculum of approximately 
5 × 105 cfu/ml. MIC readings were taken at 18 h and the 
MIC was defined as the lowest concentration of the anti-
biotic at which there was no visible growth. Assays were 
conducted in triplicate.
Fractional inhibitory concentration (FIC) determinations
FIC values were determined by conducting broth micro-
dilution checkerboard assays, as described by Orhan 
et  al. [8]. Briefly, two antimicrobials were combined on 
the same microtitre plate, such that antimicrobial A was 
serially diluted vertically along the microtitre plate and 
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antimicrobial B serially diluted from right to left horizon-
tally along the microtitre plate, resulting in a mix of the 
two antimicrobials at different concentrations in different 
wells in the same microtitre plate. The plates were inocu-
lated with approximately 5 × 105 cfu/ml, as described for 
the MIC assays and FIC indices determined after 18  h. 
Assays were conducted in triplicate. The antimicrobial 
interactions and FIC values were interpreted as syner-
gistic, partial synergistic, additive, indifferent or antago-
nistic, as described by Orhan et  al. and Bacon et  al. [8, 
9]. FIC values for thuricin CD-vancomycin combinations 
against R027, Liv022 R106 and TL178 R002 were deter-
mined and reported in our previous study [7].
XTT assays to determine the efficacy of antimicrobials 
and antimicrobial combinations against C. difficile biofilms
The activities of the above-mentioned antimicrobials 
were also assessed against C. difficile 20291 R027, Liv022 
R106, TL178 R002, DPC6350 and VPI10463 biofilms 
using the XTT (2-methyloxy-4-nitro-5-sulfophenyl]-
2H-tetrazolium-5-carboxanilide)-menadione reduction 
assay, as described by Field et  al. with minor modifica-
tions [10]. Briefly, C. difficile biofilms on 96-well micro-
titre plates were formed by incubating approximately 
5 ×  105 cfu/ml of log-phase cells in BHI broth supple-
mented with 0.1  M glucose (for R027, Liv022 R106 and 
TL178 R002) or RCM broth supplemented with 0.1  M 
glucose (for DPC6350 and VPI10463) for 72  h in an 
anaerobic workstation. After 72 h, the supernatants were 
removed from the wells and the biofilms washed very 
gently with phosphate buffered saline (PBS) to elimi-
nate planktonic cells. Antimicrobials and antimicrobial 
combinations resuspended in BHI broth supplemented 
with 0.1  M glucose (or RCM broth supplemented with 
0.1 M glucose for strains DPC6350 and VPI10463) were 
added to the wells and allowed to incubate for 24 h under 
anaerobic conditions. After 24 h, the supernatants were 
removed and the biofilms washed extremely gently with 
PBS. At this point, 100 µl of XTT was added to each well 
and incubated in the dark under anaerobic conditions for 
2  h. After 2  h, OD492 readings were taken using a plate 
reader (BioTek Synergy HT, Vermont, USA). At least five 
independent replicates were used for each strain and 
each condition tested. Statistically significant differences 
between untreated and treated samples were determined 
using Student’s t test.
Results
Minimum inhibitory concentrations (MICs) of various 
antimicrobials against C. difficile strains
The MIC range for thuricin CD against the C. difficile 
strains used in this study was 0.703–2.812  µg/ml (125–
500  nM), whereas the MICs for vancomycin against 
the C. difficile strains ranged between 0.464–1.856  µg/
ml (312–1250  nM)(Table  1). In terms of molar concen-
trations, it was found that rifampicin was consistently 
the most potent antimicrobial tested against the C. dif-
ficile strains tested in this study, with MIC values in the 
low nanomolar range (values ranged between 0.0016–
0.0064 µg/ml)(Table 1). Rifampicin MICs determined by 
the E test were found to be between 0.002–32 μg/ml in 
a study conducted by O’Connor et  al. while Huhulescu 
and co-workers reported rifampicin MIC values ranging 
from ≤0.002 to ≥32 µg/ml against a variety of C. difficile 
isolates, also based on E tests [11, 12]. Tigecycline and 
teicoplanin were found to have largely similar MIC values 
against C. difficile in this study, with tigecycline values 
ranging from 0.091 to 0.366  µg/ml and teicoplanin val-
ues ranging between 0.146 and 0.292 µg/ml (Table 1). The 
MIC90 range for tigecycline against C. difficile has been 
reported to be between 0.03 and 0.25 μg/ml in other stud-
ies [13, 14]. The MICs of teicoplanin against C. difficile 
were between 0.023 and 0.75 μg/ml in previous studies, 
whereas de Lalla and co-workers documented MIC50 and 
MIC90 values of teicoplanin against C. difficile to be less 
than 0.125–0.25 μg/ml [15–17]. In terms of molar values, 
nitazoxanide was consistently the least potent antimicro-
bial against C. difficile strains in this study, with the MIC 
value range between 390 and 1560  nM (0.12–0.479  µg/
ml). The MIC range for nitazoxanide against C. difficile 
was found to be between 0.03 and 1.0  µg/ml in other 
studies [13, 18]. As mentioned previously, thuricin CD 
Table 1 Minimum inhibitory concentration (MIC) values of antimicrobials against C. difficile strains
MICs of various antimicrobials against planktonic cells of C. difficile strains expressed in nanomolar concentrations and also in μg/ml in parentheses and in italics
The MICs of thuricin CDa  and vancomycinb against strains 20291 R027, Liv022 R106 and TL178 R002 were already determined and reported in our previous study [7]
Antimicrobial/ 
Strain
Teicoplanin  
nM (μg/ml)
Tigecycline  
nM (μg/ml)
Nitazoxanide  
nM (μg/ml)
Rifampicin  
nM (μg/ml)
Thuricin CDa  
nM (μg/ml)
Vancomycinb 
nM (μg/ml)
20291 R027 78 (0.146) 312 (0.183) 1560 (0.479) 8 (0.0064) 125 (0.703) 625 (0.928)
Liv022 R106 156 (0.292) 625 (0.366) 780 (0.239) 2 (0.0016) 250 (1.406) 1250 (1.856)
TL178 R002 156 (0.292) 625 (0.366) 390 (0.120) 2 (0.0016) 500 (2.812) 625 (0.928)
DPC6350 156 (0.292) 156 (0.091) 1560 (0.479) 2 (0.0016) 125 (0.703) 625 (0.928)
VPI10463 78 (0.146) 156 (0.091) 780 (0.239) 2 (0.0016) 125 (0.703) 312 (0.464)
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and vancomycin display potent anti-C. difficile activity in 
terms of molar MIC concentrations. However, vancomy-
cin and, thuricin CD in particular (due to its two-com-
ponent nature and consequent high molecular weight), 
appear the least potent antimicrobials against C. difficile 
when MIC values are expressed in µg/ml (Table 1).
Determination of fractional inhibitory concentration (FIC) 
indices of various antimicrobial combinations against C. 
difficile strains
Fractional inhibitory concentrations (FIC) values were 
also determined by using broth microdilution checker-
board assays in this study, as described in Orhan et  al. 
[8], and FIC values and effects interpreted as described 
in Bacon et  al. [9] (Table  2). Merely partial synergis-
tic (0.5 ≤  FIC ≤  0.75), additive (0.75 ≤  FIC ≤  1.0) and 
indifferent effects (1.01  ≤  FIC  ≤  2.0) were obtained in 
this study and no antagonistic effects (FIC  ≥  2.0) were 
observed. It should be emphasised, however, that check-
erboard assays referred to here were conducted with 
planktonic C. difficile cells, to facilitate a comparison 
between these results and those with C. difficile biofilms 
described below.
Efficacy of antimicrobials independently against C. difficile 
biofilms
The activities of the above-mentioned antimicrobi-
als were also assessed against C. difficile 20291 R027, 
TL178 R002, Liv022 R106, DPC6350 and VPI10463 bio-
films using the XTT (2-methyloxy-4-nitro-5-sulfophen 
yl]-2H-tetrazolium-5-carboxanilide)-menadione reduc-
tion assay (Figs.  1, 2, 3, 4 and 5). Against 20291 R027, 
it was found that each of the antimicrobials, with the 
exception of vancomycin and teicoplanin, were effective 
at decreasing the viability of the biofilms at 4x the MIC 
concentration (Fig.  1). At 2x the MIC concentrations, 
the antimicrobials used were less potent at reducing the 
R027 biofilm cell viability, with teicoplanin, vancomycin 
and tigecycline being the least effective (Fig. 1). Clostrid-
ium difficile DPC6350 was determined to be a relatively 
strong biofilm former and it was found that teicoplanin, 
tigecycline, vancomycin and thuricin CD were particu-
larly effective at targeting biofilms of this strain at both 4x 
and 2x MIC concentrations (all P < 0.002)(Fig. 2).
C. difficile Liv022 R106 was a relatively weaker bio-
film former compared to strains 20291 and DPC6350 
(Fig.  3). It was found that thuricin CD at 4x MIC was 
effective at reducing the viability of the biofilm relative to 
the untreated control (P  <  0.05). We also observed that 
although there was a minor reduction in R106 biofilm 
viability after treatment with nitazoxanide, vancomycin, 
teicoplanin, tigecycline and rifampicin at 4x MIC, these 
reductions were not statistically significant (all P > 0.05) 
(Fig. 3).
Clostridium difficile TL178 R002 was found to be a 
weak biofilm former, compared to strains R027 and 
DPC6350 (Fig. 4). Against TL178 R002, it was apparent 
that none of the antibiotics were effective at reducing the 
biofilm viability when used independently, at concen-
trations of 4x MIC or 2x MIC. Thuricin CD at 4x MIC 
elicited a minor reduction in R002 biofilms relative to the 
untreated control but this difference was not significant 
(P > 0.05) (Fig. 4).
Finally, C. difficile VPI10463 was found to be the weak-
est biofilm former amongst the strains tested under 
our incubation conditions (Fig.  5). Thuricin CD at 4x 
MIC and 2x MIC elicited a reduction in the viability of 
VPI10463 biofilms (both P  <  0.05). Amongst the anti-
biotics, 4x MIC nitazoxanide was the only antibiotic 
that led to a significant reduction in VPI10463 biofilms 
(P < 0.05), whereas the other antibiotics were unable to 
do so (Fig. 5).
Efficacy of antimicrobials in paired combinations against C. 
difficile biofilms
In addition to assessing the potencies of the above-
mentioned antimicrobials used independently against 
20291 R027 biofilms, we also combined the sactibi-
otic thuricin CD at 2x the MIC concentration with 2x 
MIC of each of the antibiotics vancomycin, rifampicin, 
Table 2 Fractional inhibitory concentration (FIC) values of various antimicrobial combinations against C. difficile
Antimicrobial combination effects are indicated in parentheses
PS partial synergy (0.5 ≤ FIC ≤ 0.75), Ad additive effects (0.75 ≤ FIC ≤ 1.0), I indifferent effects (1.01 ≤ FIC ≤ 2.0)
FIC indices of athuricin CD-teicoplanin, bthuricin CD-tigecycline, cthuricin CD-rifampicin dthuricin CD-nitazoxanide and ethuricin CD-vancomycin against C. difficile 
strains. fThuricin CD-vancomycin FIC values against strains 20291 R027, Liv022 R106 and TL178 R002 were already determined and reported in our previous study [7]
Antimicrobial combination/ 
C. difficile strain
TCD-Teicoa ΣFIC TCD-Tigb ΣFIC TCD-Rifc ΣFIC TCD-Nitazd ΣFIC TCD-Ve, i ΣFIC
20291 R027 0.75 (PS)f 1.0 (Ad)g 1.0 (Ad) 1.01–2 (I)h 1.01–2 (I)
Liv022 R106 1.01–2 (I) 1.01–2 (I) 1.01–2 (I) 1.01–2 (I) 1.0 (Ad)
TL178 R002 1.01–2 (I) 1.01–2 (I) 1.01–2 (I) 1.0 (Ad) 1.01–2 (I)
DPC6350 1.01–2 (I) 1.01–2 (I) 1.01–2 (I) 1.0 (Ad) 1.01–2 (I)
VPI10463 1.01–2 (I) 1.01–2 (I) 1.01–2 (I) 1.0 (Ad) 1.01–2 (I)
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teicoplanin, tigecycline or nitazoxanide (Figs.  1, 2, 3, 
4 and 5). Combinations of 2x MIC of thuricin CD and 
2x MIC of rifampicin against C. difficile R027 biofilms 
appeared to be potent, as the combination led to sta-
tistically significant differences in terms of reduction of 
the biofilm, relative to 2x MIC of the two antimicrobials 
used independently (P  <  0.0001 and 0.005, respectively) 
and relative to the untreated control (P < 0.0001)(Fig. 1). 
Similarly, there were statistically significant differences 
between the combination of 2x MIC thuricin CD and 
2x MIC tigecycline, relative to 2x MIC of the antimicro-
bials used independently (P  <  0.05 and 0.005, respec-
tively) and relative to the untreated control (P < 0.0001), 
although the difference was less pronounced than that 
of thuricin CD-rifampicin combinations (Fig.  1). Thu-
ricin CD-teicoplanin combinations resulted in similar 
effects as those resulting from the thuricin CD-tigecy-
cline combinations described above (Fig. 1).With respect 
to thuricin CD-vancomycin combinations against R027 
biofilms, the decrease in viability of the biofilm relative 
Fig. 1 Activity of antimicrobials independently, and in combination with thuricin CD, against C. difficile 20291 R027 biofilms. Effects of various 
antimicrobials on the viability of C. difficile 20291 R027 biofilms, using the XTT-menadione viability assay assessed by measuring OD492 values. 
Antimicrobials were used at 4x and 2x MIC as well as combinations of 2x MIC thuricin CD with each of the antibiotics at 2x MIC. Asterisks indicate 
statistically significant reductions in biofilm viabilty relative to the untreated control, determined using the Student’s t test; *P < 0.05, **P < 0.01, 
***P < 0.001. TCD thuricin CD, Van vancomycin, Rif rifampicin, Teico teicoplanin, Tig tigecycline, Nit nitazoxanide
Fig. 2 Activity of antimicrobials independently, and in combination with thuricin CD, against C. difficile DPC6350 biofilms. Effects of various antimi-
crobials on the viability of C. difficile DPC6350 biofilms, using the XTT-menadione viability assay assessed by measuring OD492 values. Antimicrobi-
als were used at 4x and 2x MIC as well as combinations of 2x MIC thuricin CD with each of the antibiotics at 2x MIC. Asterisks indicate statistically 
significant reductions in biofilm viabilty relative to the untreated control, determined using the Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001. 
TCD thuricin CD, Van vancomycin, Rif rifampicin, Teico teicoplanin, Tig tigecycline, Nit nitazoxanide
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to 2x MIC thuricin CD was not statistically significant 
(P > 0.05) but was significant when compared to 2x MIC 
vancomycin used independently (P < 0.05) and relative to 
the untreated control (P < 0.005). Interestingly, thuricin 
CD-nitazoxanide combinations against C. difficile R027 
biofilms resulted in an apparent antagonistic effect, as 2x 
MIC of thuricin CD combined with 2x MIC of nitazoxa-
nide was ineffective at decreasing the viability of the bio-
film, relative to the use of 2x MIC thuricin CD (P < 0.005) 
or 2x MIC nitazoxanide alone (P < 0.005). We sought to 
Fig. 3 Activity of antimicrobials independently, and in combination with thuricin CD, against C. difficile Liv022 R106 biofilms. Effects of various 
antimicrobials on the viability of C. difficile Liv022 R106 biofilms, using the XTT-menadione viability assay assessed by measuring OD492 values. 
Antimicrobials were used at 4x and 2x MIC as well as combinations of 2x MIC thuricin CD with each of the antibiotics at 2x MIC. Asterisks indicate 
statistically significant reductions in biofilm viabilty relative to the untreated control, determined using the Student’s t test; *P < 0.05, **P < 0.01, 
***P < 0.001. TCD thuricin CD, Van vancomycin, Rif rifampicin, Teico teicoplanin, Tig tigecycline, Nit nitazoxanide
Fig. 4 Activity of antimicrobials independently, and in combination with thuricin CD, against C. difficile TL178 R002 biofilms. Effects of various anti-
microbials on the viability of C. difficile TL178 R002 biofilms, using the XTT-menadione viability assay assessed by measuring OD492 values. Antimicro-
bials were used at 4x and 2x MIC as well as combinations of 2x MIC thuricin CD with each of the antibiotics at 2x MIC. Asterisks indicate statistically 
significant reductions in biofilm viability relative to the untreated control, determined using the Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001. 
TCD thuricin CD, Van vancomycin, Rif rifampicin, Teico teicoplanin, Tig tigecycline, Nit nitazoxanide
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assess whether higher concentrations of thuricin CD (8x 
MIC) combined with higher concentrations of nitazoxa-
nide (8x MIC) resulted in a similar apparently antago-
nistic effect as seen with 2x thuricin CD-2x nitazoxanide 
combinations against R027 biofilms. However, we found 
that 8x MIC thuricin CD-8x MIC nitazoxanide combina-
tions were potent against R027 biofilms, with a marked 
reduction in viability, relative to the untreated control 
(P < 0.001)(Fig. 1).
Against biofilms of strain DPC6350, we determined 
that 2x MIC thuricin CD combined with 2x MIC of 
each of the five antibiotics elicited a decrease in biofilm 
viability (all P < 0.001) (Fig. 2). Combinations of 8x MIC 
thuricin CD combined with 8x MIC nitazoxanide were 
also effective against DPC6350 biofilms, relative to the 
untreated control (P < 0.001). As was the case with 20291 
biofilms, thuricin CD-rifampicin combinations appeared 
to be the most effective at targeting DPC6350 biofilms 
(Fig. 2).
With respect to the antimicrobial combinations against 
C. difficile Liv022 R106 biofilms, it was found that none 
of the antibiotics combined with thuricin CD led to 
statistically significant reductions in biofilm viability, 
when compared to the untreated control (all P  >  0.05)
(Fig.  3). In contrast to strains 20291 and DPC6350, the 
most effective combination against Liv022 R106 biofilms 
appeared to be 2x MIC thuricin CD combined with 2x 
MIC nitazoxanide and the least effective was 2x MIC 
thuricin CD with 2x MIC rifampicin. Overall, there were 
no statistically significant improvements in the potency 
of the antibiotic combinations with thuricin CD against 
Liv022 R106 biofilms, when compared to the potency of 
2x thuricin CD used independently (all P  >  0.05). High 
concentrations of thuricin CD combined with high con-
centrations of nitazoxanide (both 8x MIC) were potent at 
decreasing the viability of Liv022 R106 biofilms, relative 
to the untreated control (P < 0.005) (Fig. 3).
Similar to strain Liv022 R106, the combinations of 2x 
MIC of the different antibiotics with 2x MIC thuricin CD 
failed to result in any reductions in TL178 R002 biofilm 
viability, relative to the untreated control (all P  >  0.05)
(Fig.  4). Even high concentrations of thuricin CD (8x 
MIC) combined with high concentrations of nitazoxanide 
(8x MIC) was ineffective at reducing TL178 R002 bio-
film viability. Furthermore, there was no improvement in 
terms of potency against TL178 R002 biofilms, when 2x 
MIC thuricin CD was combined with 2x MIC of each of 
the antibiotics, compared to 2x MIC thuricin CD used on 
its own (Fig.  4). Finally, against strain VPI10463, which 
was the weakest biofilm former evaluated in this study, 
it was determined that thuricin CD-rifampicin combina-
tions were the most effective against biofilms of this strain 
(P < 0.005), relative to the untreated control (Fig. 5).
Discussion
The aim of the study was to evaluate the efficacy of one 
bacteriocin (thuricin CD) and 5 antibiotics (teicoplanin, 
tigecycline, vancomycin, rifampicin and nitazoxanide) 
when used independently and when combined at low 
concentrations together against C. difficile biofilms, as 
Fig. 5 Activity of antimicrobials independently, and in combination with thuricin CD, against C. difficile VPI10463biofilms. Effects of various antimi-
crobials on the viability of C. difficile VPI10463 biofilms, using the XTT-menadione viability assay assessed by measuring OD492 values. Antimicrobi-
als were used at 4x and 2x MIC as well as combinations of 2x MIC thuricin CD with each of the antibiotics at 2x MIC. Asterisks indicate statistically 
significant reductions in biofilm viabilty relative to the untreated control, determined using the Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001. 
TCD thuricin CD, Van vancomycin, Rif rifampicin, Teico teicoplanin, Tig tigecycline, Nit nitazoxanide
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well as against planktonic cells of the same strains. As 
antibiotics are expensive to use in clinical settings, we 
attempted to find alternative antimicrobial combina-
tions which work well together at relatively low concen-
trations (2x MIC each), in an attempt to diminish the 
viability of such biofilms. Furthermore, since biofilms 
often show resistance to antibiotics used on their own, 
our objective was to search for effective antimicrobial 
combinations that could potentiate each other’s effects 
to circumvent these problems of antimicrobial resistance. 
We postulated that using antimicrobial combinations at 
low concentrations would provide insights into effective 
therapeutic options with a view to targeting C. difficile 
biofilms.
It was particularly noteworthy there were differences 
amongst C. difficile strains in their abilities to form 
strongly adherent biofilms and variations in the sensitivi-
ties of biofilms of these different C. difficile strains that 
we tested to the different antibiotics used either inde-
pendently or in paired combinations. Various factors are 
likely to be involved in governing the strengths of bio-
films formed, including the presence of glucose, sporula-
tion and even sub-lethal doses of antibiotics [3, 5, 19, 20]. 
This potential stimulation of C. difficile biofilm formation 
by sub-lethal concentrations of antibiotics may occur in 
treatment regimens involving pulsed or tapered dosing 
of antibiotics against CDI, whereby antibiotics are likely 
to be present at sub-lethal doses and thus can contribute 
to treatment failure [3, 19]. Clostridium difficile R20291 
R027 and DPC6350 were the strongest biofilm form-
ers amongst the strains we tested in this study. C. diffi-
cile R20291 R027 has also previously been shown to be 
a relatively strong biofilm former in other studies [2, 3, 
5]. A stronger ability to form adherent biofilms may be a 
contributing factor involved in greater degrees of coloni-
zation of this epidemic-associated strain in the gut [3, 5].
With respect to the antimicrobials used independently 
in our study, the glycopeptide vancomycin was found to 
be ineffective against biofilms of four of the five strains 
we assessed. Similar to our findings, Dapa and co-work-
ers had also previously reported that C. difficile biofilms 
display attenuated sensitivity to vancomycin [5]. Indeed, 
biofilms are generally more resistant to antibiotics and 
studies by Semenyuk et al. had reported that C. difficile 
biofilms also exhibit increased resistance to the anti-
biotic metronidazole, relative to C. difficile planktonic 
cells grown in liquid broth media [21]. The study by 
Dapa et al. indicates that the structure and organisation 
of the matrix in C. difficile biofilms is likely to play a role 
in mediating resistance to antibiotics, as such matrices 
can prevent penetration of the antimicrobial reaching 
the bacteria within [5, 22]. In addition, the physiologi-
cal state of the bacteria present in the biofilm as well as 
the presence of persister cells are likely to have a role 
in attenuated sensitivity to antibiotics [23]. Interest-
ingly, the semi-synthetic glycopeptide, teicoplanin, was 
found to be effective only against biofilms of C. difficile 
strain DPC6350, while being ineffective against the other 
strains in our study. Thus, it appears that the glycopep-
tide group of antibiotics can be ineffective at targeting 
biofilms of a number of C. difficile strains. The thiazolide 
antimicrobial, nitazoxanide, was effective at reducing the 
biofilm viability of three of the five strains we tested in 
this study and it was determined that tigecycline (a mem-
ber of the glycylcycline group of antibiotics) was potent 
against 20291 R027 and DPC6350, while being ineffec-
tive against biofilms of strains TL178 R002, Liv022 R106 
and VPI10463. It may be the case that tigecycline has a 
greater ability to target strongly-adherent biofilms, such 
as those formed by R027, DPC6350, and is ineffective 
against weakly-adherent biofilms. Similar to tigecycline, 
rifampicin (belonging to the rifamycin group of antibi-
otics) also exhibited more potency against the stronger 
biofilms of R027 and DPC6350, while only being mar-
ginally effective against Liv022 R106 biofilms and inef-
fective against the weak biofilms of TL178 R002 and 
VPI10463. It is plausible that altered growth rates of cells 
within these C. difficile biofilms caused by genetic muta-
tions leads to attenuated sensitivity of certain strains to 
teicoplanin, tigecycline and rifampicin. Thus, it is clear 
that biofilms of different C. difficile strains display vary-
ing degrees of sensitivity to the different antibiotics when 
used on their own but the precise mechanisms of sensi-
tivity remain largely unknown.
With respect to antimicrobial combinations used in this 
study, variations in sensitivities of biofilms of different 
strains to the antimicrobial combinations were also appar-
ent. The most striking difference was that while thuricin 
CD combined with either teicoplanin, tigecycline, vanco-
mycin or rifampicin was effective against stronger biofilms 
of strains 20291 R027 and DPC6350, such combinations 
were largely ineffective against the relatively weaker bio-
films of TL178 R002, Liv022 R106 and VPI10463. Inter-
estingly, 2x thuricin CD-2x nitazoxanide combinations 
were particularly ineffective against R027 biofilms. It may 
be the case that the addition of thuricin CD to nitazoxa-
nide at low concentrations somehow interferes with the 
ability of nitazoxanide to target the pyruvate:ferredoxin 
oxidoreductase system in C. difficile R027 at such concen-
trations. Alternatively, it could be the case that nitazoxa-
nide prevents thuricin CD from reaching a target receptor 
in C. difficile, thus leading to a lack of efficacy against C. 
difficile R027 biofilms when combined together, resulting 
in apparent antagonistic effects at these concentrations. 
Furthermore, while higher concentrations of these anti-
microbials combined (8x MIC thuricin CD with 8x MIC 
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nitazoxanide) were effective against biofilms of R027, 
DPC6350 and Liv022 R106, this combination at higher 
concentrations was still ineffective against the weakest 
biofilms of TL178 R002 and VPI10463. Thus, it is appar-
ent that there are strain-specific as well as concentration-
dependent variations with regards to sensitivities of C. 
difficile biofilms to different antimicrobials and antimicro-
bial combinations. Since the XTT-menadione reduction 
assay determines the level of viability of C. difficile bio-
films, it provides insights into the amount of a biofilm that 
is still metabolically active, subsequent to antimicrobial 
challenges and thus is likely to provide a realistic picture 
regarding the potency of antimicrobials against biofilms 
in vivo [24–27]. The precise mechanism of action involved 
in thuricin CD-nitazoxanide against C. difficile planktonic 
cells and biofilms remains unclear however and merits 
further investigation in future studies.
With respect to utilising FIC values against C. difficile 
planktonic cells as a predictor of effective combinations 
against biofilms of the same strains, the partial synergis-
tic and additive effects seen with thuricin CD-teicopla-
nin, thuricin CD-rifampicin and thuricin CD-tigecycline 
combinations against C. difficile R027 planktonic cells 
are consistent with additive effects against R027 biofilms 
(Fig.  1; Table  2). Combinations of the sactibiotic thu-
ricin CD with vancomycin, rifampicin, tigecycline and 
teicoplanin may enable one of the antimicrobials to gain 
access through the complex matrix and allow the anti-
microbial to exert its killing effect on the R027 biofilm, 
thereby leading to a reduction in biofilm viability. In con-
trast, there doesn’t appear to be a correlation between the 
additive effects (FIC 1.0) obtained with thuricin CD-van-
comycin combinations against planktonic cells of Liv022 
R106 and the combination against biofilms of the same 
strain. In addition, even though thuricin CD combined 
with rifampicin resulted in indifferent effects (FIC 1.01–
2) against planktonic cells of DPC6350, it is apparent that 
this combination displayed ameliorated potency against 
DPC6350 biofilms, compared to either 2x MIC thuricin 
CD or 2x MIC rifampicin. Finally, while thuricin CD-
nitazoxanide combinations resulted in additive effects 
(FIC 1.0) against planktonic cells of DPC6350, combina-
tions of 2x MIC thuricin CD with 2x MIC nitazoxanide 
did not exhibit enhanced activity when compared to 2x 
MIC thuricin CD used independently against biofilms of 
this strain (P  >  0.05). Similar trends were noted against 
planktonic cells and biofilms of strains TL178 R002 and 
VPI10463. The variations between planktonic cells and 
biofilms could be due to differences in the mechanisms of 
action of thuricin CD-nitazoxanide combinations against 
planktonic cells, as opposed to the two antimicrobials 
targeting a complex multi-layered matrix that exists in a 
C. difficile biofilm.
Conclusions
In conclusion, this is the first study assessing the antimi-
crobial effect of a sactibiotic bacteriocin and the antibi-
otics nitazoxanide, tigecycline and teicoplanin against C. 
difficile biofilms. Overall, it is encouraging to note from 
this study that a number of C. difficile strains have a rela-
tively weak ability to form strongly adherent biofilms, 
in comparison to other pathogens such as Streptococcus 
mutans, Staphylococcus aureus and Pseudomonas aer-
uginosa, which are notorious biofilm producers [28–30]. 
It is also encouraging to note that four of the five anti-
microbial combinations we tested (with the exception of 
thuricin CD-nitazoxanide) appeared to be highly effec-
tive against two of the stronger C. difficile biofilm form-
ers, 20291 R027 and DPC6350. It is apparent from this 
study that, not only are there variations between different 
C. difficile strains in their abilities to form biofilms, there 
are also variations in terms of sensitivities of biofilms 
of different strains to several antimicrobial treatment 
options. Such variations seen with regards to the poten-
cies of the different antimicrobials/antimicrobial combi-
nations against these different strains may be due to the 
relative strengths of the biofilms that the antimicrobials 
target. Furthermore, the mechanism of action involved in 
effective antimicrobial combinatorial therapy is likely to 
be different against planktonic cells, compared to cells in 
biofilms. While it is clear that much remains to be elu-
cidated with respect to the precise mechanisms govern-
ing antimicrobial sensitivity and antimicrobial resistance 
within C. difficile biofilms, overall, this study could form 
the basis for the development of successful antimicrobial 
combination therapy strategies, with a view to target-
ing C. difficile biofilms. The findings presented in this 
study could have implications with regards to reducing 
the recurrence rates of CDI, particularly in cases where 
a strong C. difficile biofilm former is contributing to 
increased recurrence rates.
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